Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Free Cash Flow (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Free Cash Flow for 7 consecutive years, with -$17.8 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 62.84% to -$17.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$128.7 million through Dec 2025, up 19.23% year-over-year, with the annual reading at -$128.7 million for FY2025, 19.23% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$17.8 million at Pliant Therapeutics, up from -$21.1 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$13.9 million in Q1 2021, with the low at -$49.1 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$29.0 million, with a median of -$25.4 million recorded in 2023.
  • The sharpest move saw Free Cash Flow plummeted 357.05% in 2021, then skyrocketed 62.84% in 2025.
  • Over 5 years, Free Cash Flow stood at -$21.5 million in 2021, then tumbled by 53.42% to -$33.0 million in 2022, then rose by 21.06% to -$26.0 million in 2023, then tumbled by 83.96% to -$47.9 million in 2024, then surged by 62.84% to -$17.8 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$17.8 million, -$21.1 million, and -$40.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.